Differential Effects of Zanubrutinib and Ibrutinib on Neutrophil Antifungal Functions: Insights from Live-Cell Imaging
Journal of Innate Immunity · 14.08.2026 · 18 (1) · 448-460
DOI: 10.1159/jin/adhag001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Innate Immunity, online erschienen am 14.08.2026. Verfasst von Benoit S Marteyn und 8 weiteren Autor:innen. Beteiligte Einrichtung: Université de Strasbourg, Institut de Biologie Moléculaire et Cellulaire (IBMC), CNRS UPR9002, Strasbourg, France, marteyn@pasteur.fr. Hauptthemen laut MEDLINE: Neutrophils, Adenine, Piperidines, Aspergillus fumigatus. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Bruton tyrosine kinase inhibitors (BTKi) impair anti-Aspergillus immune responses and increase the risk of invasive fungal infections (IFI). More selective second-generation BTKi have fewer off-target effects thus a better tolerance than ibrutinib. Though clinical data suggest the incidence of IFI is lower with second-generation BTKi, whether they have less impact on antifungal immunity remains unclear.
Methods
We studied the activation phenotype and behavior of human neutrophils in vitro with fungal extracts or living Aspergillus fumigatus in the presence of either ibrutinib or zanubrutinib, a more selective second-generation BTKi, using various approaches, including live microscopy.
Results
Both molecules inhibited the activation-induced phenotypic changes in neutrophils following exposure to hyphae. Similarly, ibrutinib and zanubrutinib impaired neutrophil-mediated inhibition of conidia germination. By contrast, live neutrophil imaging showed that neutrophils exposed to ibrutinib but not zanubrutinib kept a round morphology, suggesting a defective activation, were less mobile, and showed impaired conidia phagocytosis.
Conclusion
We confirm here that ibrutinib and zanubrutinib inhibit neutrophil antifungal activity, strongly suggesting that BTK plays a central role. However, subtle differences between ibrutinib and zanubrutinib were evidenced using live microscopy, which might indicate additional off-target effects, and potentially partially explain the lower incidence of IFI with zanubrutinib; the clinical relevance remains to be determined.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université de Strasbourg, Institut de Biologie Moléculaire et Cellulaire (IBMC), CNRS UPR9002, Strasbourg, France, marteyn@pasteur.fr.
- Institut Pasteur, INSERM U1225, Unité de Pathogenèse des Infections Vasculaires, Paris, France, marteyn@pasteur.fr.
- University of Strasbourg Institute for Advanced Study (USIAS), Paris, France, marteyn@pasteur.fr.
- INSERM U1015, Institut Gustave Roussy, Villejuif, France.
- Université de Strasbourg, Institut de Biologie Moléculaire et Cellulaire (IBMC), CNRS UPR9002, Strasbourg, France.
- Université de Strasbourg, Institut de Biologie Moléculaire et Cellulaire (IBMC), CNRS UPR3572, Strasbourg, France.
Zitieren
APA
Marteyn, B. S., Silvin, A., Thahouly, T., Broussaudier, N., Fauny, J. D., Valente Barroso, M., Fontaine, T., Laribi, K., & Ghez, D. (2026). Differential Effects of Zanubrutinib and Ibrutinib on Neutrophil Antifungal Functions: Insights from Live-Cell Imaging. Journal of Innate Immunity, 18(1), 448-460. https://doi.org/10.1159/jin/adhag001
Vancouver
Marteyn BS, Silvin A, Thahouly T, Broussaudier N, Fauny JD, Valente Barroso M, et al. Differential Effects of Zanubrutinib and Ibrutinib on Neutrophil Antifungal Functions: Insights from Live-Cell Imaging. Journal of Innate Immunity. 2026;18(1):448-460. doi:10.1159/jin/adhag001
BibTeX
@article{Marteyn2026,
author = {Marteyn, Benoit S and Silvin, Aymeric and Thahouly, Tamou and Broussaudier, Nathan and Fauny, Jean-Daniel and Valente Barroso, Marina and Fontaine, Thierry and Laribi, Kamel and Ghez, David},
title = {Differential Effects of Zanubrutinib and Ibrutinib on Neutrophil Antifungal Functions: Insights from Live-Cell Imaging},
journal = {Journal of Innate Immunity},
year = {2026},
volume = {18},
number = {1},
pages = {448--460},
doi = {10.1159/jin/adhag001}
}
EUVIMED